Preserved thrombin-inducible platelet activation in thienopyridine-treated patients

European Journal of Clinical Investigation

Volumn 43, Issue 7, 2013, Pages 689-697

  Gremmel, Thomas ^a   Kopp, Christoph W ^a   Seidinger, Daniela ^a   Koppensteiner, Renate ^a   Steiner, Sabine ^a   Panzer, Simon ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Angioplasty; Platelet reactivity; Thienopyridines; Thrombin

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; CLOPIDOGREL; FIBRINOGEN RECEPTOR; PADGEM PROTEIN; PRASUGREL; THIENOPYRIDINE DERIVATIVE; THROMBIN RECEPTOR ACTIVATING PEPTIDE 6; VASODILATOR STIMULATED PHOSPHOPROTEIN;

ADULT; AGED; ANGIOPLASTY; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR STENT; ELECTRODE; FEMALE; HUMAN; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MONOCYTE; PLATELET REACTIVITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; TREATMENT RESPONSE;

ADENOSINE DIPHOSPHATE; AGED; ANGIOPLASTY; ASPIRIN; BLOOD PLATELETS; CARDIOVASCULAR DISEASES; FEMALE; HUMANS; INTEGRIN BETA3; MALE; MIDDLE AGED; P-SELECTIN; PEPTIDE FRAGMENTS; PIPERAZINES; PLATELET ACTIVATION; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PLATELET MEMBRANE GLYCOPROTEIN IIB; PURINERGIC P2Y RECEPTOR ANTAGONISTS; STENTS; THIOPHENES; THROMBIN; TICLOPIDINE;

EID: 84878934386     PISSN: 00142972     EISSN: 13652362     Source Type: Journal    
DOI: 10.1111/eci.12094     Document Type: Article

References (35)

1. Bhatt DL, Fox KA, Hacke W, Berger PB, Black HR, Boden WE et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med 2006;354:1706-17.
2. Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007;357:2001-15.
3. Bonello L, Paganelli F, Arpin-Bornet M, Auquier P, Sampol J, Dignat-George F et al. Vasodilator-stimulated phosphoprotein phosphorylation analysis prior to percutaneous coronary intervention for exclusion of postprocedural major adverse cardiovascular events. J Thromb Haemost 2007;5:1630-6.
4. Sibbing D, Braun S, Morath T, Mehilli J, Vogt W, Schomig A et al. Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis. J Am Coll Cardiol 2009;53:849-56.
5. Aradi D, Komocsi A, Vorobcsuk A, Rideg O, Tokes-Fuzesi M, Magyarlaki T et al. Prognostic significance of high on-clopidogrel platelet reactivity after percutaneous coronary intervention: systematic review and meta-analysis. Am Heart J 2010;160:543-51.
6. Bonello L, Pansieri M, Mancini J, Bonello R, Maillard L, Barnay P et al. High on-treatment platelet reactivity after prasugrel loading dose and cardiovascular events after percutaneous coronary intervention in acute coronary syndromes. J Am Coll Cardiol 2011;58:467-73.
7. Abbate R, Cioni G, Ricci I, Miranda M, Gori AM. Thrombosis and acute coronary syndrome. Thromb Res 2012;129:235-40.
8. Kahn ML, Nakanishi-Matsui M, Shapiro MJ, Ishihara H, Coughlin SR. Protease-activated receptors 1 and 4 mediate activation of human platelets by thrombin. J Clin Invest 1999;103:879-87.
9. Dormann D, Clemetson KJ, Kehrel BE. The GPIb thrombin-binding site is essential for thrombin-induced platelet procoagulant activity. Blood 2000;96:2469-78.
10. Leger AJ, Covic L, Kuliopulos A. Protease-activated receptors in cardiovascular diseases. Circulation 2006;114:1070-7.
11. Vandendries ER, Furie BC, Furie B. Role of P-selectin and PSGL-1 in coagulation and thrombosis. Thromb Haemost 2004;92:459-66.
12. Michelson AD, Barnard MR, Krueger LA, Valeri CR, Furman MI. Circulating monocyte-platelet aggregates are a more sensitive marker of in vivo platelet activation than platelet surface P-selectin: studies in baboons, human coronary intervention, and human acute myocardial infarction. Circulation 2001;104:1533-7.
13. Shattil SJ, Cunningham M, Hoxie JA. Detection of activated platelets in whole blood using activation-dependent monoclonal antibodies and flow cytometry. Blood 1987;70:307-15.
14. Gremmel T, Steiner S, Seidinger D, Koppensteiner R, Panzer S, Kopp CW. Comparison of methods to evaluate clopidogrel-mediated platelet inhibition after percutaneous intervention with stent implantation. Thromb Haemost 2009;101:333-9.
15. Kalb ML, Potura L, Scharbert G, Kozek-Langenecker SA. The effect of ex vivo anticoagulants on whole blood platelet aggregation. Platelets 2009;20:7-11.
16. Bonello L, Tantry US, Marcucci R, Blindt R, Angiolillo DJ, Becker R et al. Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate. J Am Coll Cardiol 2010;56:919-33.
17. Eslam RB, Reiter N, Kaider A, Eichinger S, Lang IM, Panzer S. Regulation of PAR-1 in patients undergoing percutaneous coronary intervention: effects of unfractionated heparin and bivalirudin. Eur Heart J 2009;30:1831-6.
18. Frelinger AL, Li Y, Linden MD, Tarnow I, Barnard MR, Fox ML et al. Aspirin 'resistance': role of pre-existent platelet reactivity and correlation between tests. J Thromb Haemost 2008;6:2035-44.
19. Frelinger AL 3rd, Michelson AD, Wiviott SD, Trenk D, Neumann FJ, Miller DL et al. Intrinsic platelet reactivity before P2Y12 blockade contributes to residual platelet reactivity despite high-level P2Y12 blockade by prasugrel or high-dose clopidogrel. Results from PRINCIPLE-TIMI 44. Thromb Haemost 2011;106:219-26.
20. Grove EL, Storey RF, Würtz M. Platelet function testing in atherothrombotic disease. Curr Pharm Des 2012;18:5379-91.
21. Gremmel T, Panzer S. Clinical, genetic and confounding factors determine the dynamics of the in vitro response/non-response to clopidogrel. Thromb Haemost 2011;106:211-8.
22. Siller-Matula JM, Delle-Karth G, Christ G, Neunteufl T, Maurer G, Huber K et al. Dual non-responsiveness to antiplatelet treatment is a stronger predictor of cardiac adverse events than isolated non-responsiveness to clopidogrel or aspirin. Int J Cardiol 2012; doi:10.1016/j.ijcard.2012.01.016.
23. Bonello L, Camoin-Jau L, Armero S, Com O, Arques S, Burignat-Bonello C et al. Tailored clopidogrel loading dose according to platelet reactivity monitoring to prevent acute and subacute stent thrombosis. Am J Cardiol 2009;103:5-10.
24. Siller-Matula JM, Francesconi M, Dechant C, Jilma B, Maurer G, Delle-Karth G et al. Personalized antiplatelet treatment after percutaneous coronary intervention: The MADONNA study. Int J Cardiol 2012; doi:10.1016/j.ijcard.2012.05.040.
25. Sibbing D, Bernlochner I, Schulz S, Massberg S, Schömig A, Mehilli J et al. Prognostic value of a high on-clopidogrel treatment platelet reactivity in bivalirudin versus abciximab treated non-ST-segment elevation myocardial infarction patients. ISAR-REACT 4 (Intracoronary Stenting and Antithrombotic Regimen: Rapid Early Action for Coronary Treatment-4) platelet substudy. J Am Coll Cardiol 2012;60:369-77.
26. Trenk D, Hochholzer W, Fromm MF, Chialda LE, Pahl A, Valina CM et al. Cytochrome P450 2C19 681G>A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents. J Am Coll Cardiol 2008;51:1925-34.
27. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, Ramirez C, Cavallari U, Trabetti E et al. Contribution of gene sequence variations of the hepatic cytochrome P450 3A4 enzyme to variability in individual responsiveness to clopidogrel. Arterioscler Thromb Vasc Biol 2006;26:1895-900.
28. Gurbel PA, Bliden KP, Samara W, Yoho JA, Hayes K, Fissha MZ et al. Clopidogrel effect on platelet reactivity in patients with stent thrombosis: results of the CREST study. J Am Coll Cardiol 2005;46:1827-32.
29. Gremmel T, Kopp CW, Seidinger D, Giurgea GA, Koppensteiner R, Steiner S et al. The formation of monocyte-platelet aggregates is independent of on-treatment residual agonists'-inducible platelet reactivity. Atherosclerosis 2009;207:608-13.
30. Kim S, Jin J, Kunapuli SP. Akt activation in platelets depends on Gi signaling pathways. J Biol Chem 2004;279:4186-95.
31. Tricoci P, Huang Z, Held C, Moliterno DJ, Armstrong PW, Van de Werf F et al. Thrombin-receptor antagonist vorapaxar in acute coronary syndromes. N Engl J Med 2012;366:20-33.
32. Morrow DA, Braunwald E, Bonaca MP, Ameriso SF, Dalby AJ, Fish MP et al. Vorapaxar in the secondary prevention of atherothrombotic events. N Engl J Med 2012;366:1404-13.
33. Mega JL, Braunwald E, Wiviott SD, Bassand JP, Bhatt DL, Bode C et al. Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med 2012;366:9-19.
34. Helft G, Osende JI, Worthley SG, Zaman AG, Rodriguez OJ, Lev EI et al. Acute antithrombotic effect of a front-loaded regimen of clopidogrel in patients with atherosclerosis on aspirin. Arterioscler Thromb Vasc Biol 2000;20:2316-21.
35. Badr Eslam R, Gremmel T, Schneller A, Stegfellner M, Kaider A, Mannhalter C et al. High levels of platelet-monocyte aggregates after valve replacement for aortic stenosis: relation to soluble P-selectin and P-selectin glycoprotein ligand-1 genes. Thromb Res 2012;129:453-8.